A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet Age-related Macular Degeneration

Trial Profile

A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet Age-related Macular Degeneration

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Ranibizumab (Primary) ; Dexamethasone
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms LuceDex
  • Most Recent Events

    • 13 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top